Cancer Prevention and Control Research Program

癌症预防和控制方案：项目摘要 弗吉尼亚联邦大学（VCU）梅西癌症中心（MCC）首次推出了其癌症 1991年，在癌症中心支助补助金（CCSG）内的预防和控制（CPC）计划。中共 该计划已经发展成为一个高度多学科的研究人员网络，包括人口健康 作为临床和基础科学家，该计划继续强调识别和减轻癌症 风险然而，自上一次CCSG更新以来，CPC计划在2009年招募了多名新专家。 生存研究，进一步扩大其在癌症护理连续体的影响。该方案高度 专注于解决MCC和社区的优先疾病问题-肺，胃肠道，乳腺， 和前列腺癌-以及两种显著推动癌症负担的生活方式或行为（烟草 控制和肥胖预防）。CPC的研究与MCC的社区到板凳框架保持一致， 它的使命，目标和战略计划，该计划领导中心的努力，积极参与社区， research.此外，许多中国共产党成员的意见也体现了中央对减少差距的重视。 努力了解和解决种族/族裔以及农村/城市社区之间的不平等， 两者的交集例如，在MCC的集水区内，弗吉尼亚州的农村社区 据报道，黑人/非洲裔美国人的多数少数民族人口是全国癌症热点。 由Oxana G. Palesh博士和维多利亚J.芬德利博士，CPC计划由44名科学家组成 代表医学院、药学院和人文学院的12个系， 科学该计划每年有680万美元的直接同行评审资金（250万美元来自NCI，310万美元来自其他机构）。 NIH研究所;其他机构提供1.2美元）。在本项目期间，中共党员撰写了337篇癌症- 重点研究出版物反映了这些科学家的高度合作性质; 125（37%）是内部的， 计划性的，46个（14%）是跨计划的，233个（69%）是跨机构的，161个（48%）是 与其他NCI指定的癌症中心合作。此外，CPC计划使这一数字增加了两倍， 多个主要研究者（MPI）和多个项目的奖项在当前的项目期间。他们的投资组合 现在包括16个MPI R 01/R21，两个U 01，一个UG 1，一个U 54，两个P20和一个Stand Up to Cancer奖。的 CPC计划还拥有越来越多的基于诊所和社区的干预性研究组合， 差异，支持性护理需求和生存率，以及研究人员，自2016年以来，已招募了1，663名 18,000多人参加了干预性研究，18,000多人参加了非干预性研究。在下一个CCSG项目期间 在此期间，中国共产党计划将继续围绕社区为基础和社区参与的努力锚 研究识别和降低癌症风险、增加癌症筛查并减少不同癌症 所有患者的结果和不平等。

CANCER PREVENTION AND CONTROL PROGRAM: PROJECT SUMMARY The Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) first introduced its Cancer Prevention and Control (CPC) Program within the Cancer Center Support Grant (CCSG) in 1991. The CPC Program has matured into a highly multidisciplinary nexus of investigators, including population health as well as clinical and basic scientists, and the program continues its emphasis on identifying and mitigating cancer risks. However, since the last CCSG renewal, the CPC Program has recruited multiple new experts in survivorship research, further expanding its impact across the cancer care continuum. The Program is highly focused on addressing MCC’s and the community’s priority disease concerns – lung, gastrointestinal, breast, and prostate cancers – as well as two lifestyles or behaviors significantly driving the cancer burden (tobacco control and obesity prevention). CPC research aligns well with the MCC’s Community-to-Bench framework and its mission, goals, and strategic plans, and the program leads Center efforts actively engaging the community in research. Furthermore, the Center-wide emphasis on reducing disparities is exemplified by many CPC members’ efforts to understand and address inequities among racial/ethnic as well as rural/urban communities, and notably where the two intersect. For instance, within MCC’s catchment area, it is the rural Virginia communities with majority-minority populations of Blacks/African Americans being reported among the nation’s cancer hot spots. Led by Oxana G. Palesh, PhD and Victoria J. Findley PhD, the CPC Program comprises 44 scientists representing 12 departments across the Schools of Medicine, Pharmacy, and the College of Humanities and Science. The program has $6.8M in annual, direct, peer-reviewed funding ($2.5M from NCI, $3.1M from other NIH institutes; and $1.2 from other agencies). In the current project period, CPC members authored 337 cancer- focused research publications reflecting the highly collaborative nature of these scientists; 125 (37%) were intra- programmatic, 46 (14%) were inter-programmatic, 233 (69%) were inter-institutional with 161 (48%) being collaborations with other NCI-designated cancer centers. In addition, the CPC Program has tripled the number of multi-Principal Investigator (MPI) and multi-project awards during the current project period. Their portfolio now includes 16 MPI R01/R21s, two U01s, one UG1, one U54, two P20s, and a Stand Up to Cancer award. The CPC Program also has a growing portfolio of clinic- and community-based interventional studies addressing disparities, supportive care needs, and survivorship, and investigators and since 2016 have enrolled 1,663 individuals to interventional studies and over 18,000 to non-interventional studies. During the next CCSG project period, the CPC Program will continue to anchor its efforts around community-based and community-engaged research to identify and decrease cancer risks, increase cancer screening, and reduce disparate cancer outcomes and inequities for all patients.